North America Continuous Glucose Monitoring - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the North America continuous glucose monitoring market size is expected to grow from USD 8.96 billion in 2025 to USD 10.38 billion in 2026 and is forecast to reach USD 21.56 billion by 2031 at 15.80% CAGR over 2026-2031.

This report is Segmented Into Components (Sensors, Transmitters, and Receivers), Demography (Pediatrics and Adults), End User (Hospitals & Clinics, Ambulatory Surgical & Specialty Diabetes Centers, and Home Care). Country (United States, Canada, and Mexico). The Market Forecasts are Provided in Terms of Value (USD).

North America Continuous Glucose Monitoring Market Trends and Insights

Rising Prevalence Of Diabetes & Earlier Diagnosis

Diabetes prevalence reached 38.4 million in the United States in 2024, 3.7 million in Canada in 2025, and 12.4 million in Mexico in 2025. Screening guidelines now recommend testing all adults aged 35+ and overweight adults with a risk factor, expanding the addressable base by roughly 15 million individuals. Newly diagnosed adults receive CGM within 90 days because randomized evidence shows a 0.9% additional A1c reduction versus finger-stick monitoring. Commercial insurers mirrored the science by adding first-line CGM coverage for non-insulin users in 2025. The result is a durable, long-tail driver across the North American continuous glucose monitoring market.

Rapid Uptake of Remote Monitoring & Telehealth Integration

CPT codes 99453, 99454, and 99457 reimburse remote physiologic data review, creating a recurring USD 64 monthly revenue stream per CGM patient. The Veterans Health Administration cut in-person endocrinology visits 38% after systemwide CGM-telehealth rollout in 2025 while sustaining glycemic outcomes. Kaiser Permanente's virtual clinic documented a 1.2% mean A1c drop among 4,800 enrollees by pairing CGM with asynchronous coaching. FDA guidance clarified that cloud-connected CGM platforms qualify for RPM billing, ending payer ambiguity . These forces intertwine reimbursement and telehealth growth, lifting the North American continuous glucose monitoring market.

High Device & Consumable Costs to Payers & Patients

A 10-day sensor wholesales for USD 75-95, producing yearly consumable costs up to USD 3,467 before insurance. Medicare Part B's 20% coinsurance still leaves users with USD 547-693 out-of-pocket annually. Medicaid coverage is fragmentary: 38 states reimburse CGM for type 1, only 22 for non-insulin type 2, excluding 14 million beneficiaries. Mexico's social-security formulary omits CGM entirely, forcing retail prices equal to 12-16% of the monthly minimum wage, restricting adoption to affluent urban consumers. Elevated cost, therefore, moderates penetration and dampens the North America continuous glucose monitoring market CAGR.

Other drivers and restraints analyzed in the detailed report include:

1. Sensor Miniaturization & Accuracy Breakthroughs
2. Integration With Automated Insulin Delivery Systems
3. GLP-1 Weight-Loss Drugs Reducing Testing Frequency

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Sensors accounted for 68.9% of the North America continuous glucose monitoring market share in 2025 and are projected to expand at a 16.87% CAGR through 2031. Their integration of Bluetooth Low Energy allows disposable form factors to communicate directly with smartphones, removing transmitters and trimming bill-of-material cost by 22%. Wearable sensors represent 92% of revenue; implantables grow faster at 21.3% by alleviating dermatitis complaints. Transmitters and receivers decline as stand-alone categories but persist among pediatric and senior users who lack smartphones.

Continued miniaturization underpins the competitive edge: Abbott's 5-mm Libre 3 disk and Dexcom's sleeker G7 both meet ISO 15197:2013 accuracy thresholds, positioning sensors as the hardware linchpin of the North America continuous glucose monitoring market size for the foreseeable future. FDA interoperability rules will further commoditize transmitters, concentrating value creation in sensor chemistry, wear duration, and algorithmic signal processing.

Complete Report Scope:

• By Component
  • Sensors
    • Wearable
    • Implantable
  • Transmitters
  • Receivers
• By Demography
  • Paediatric
  • Adult
• By End User
  • Hospitals & Clinics
  • Ambulatory Surgical & Specialty Diabetes Centers
  • Home Care
• By Country
  • United States
  • Canada
  • Mexico

List of Companies Covered in this Report:

1. Abbott Laboratories
2. Ascensia
3. Beta Bionics
4. Biolinq
5. Dexcom
6. Eversense (Senseonics)
7. Insulet
8. Lifescan
9. Medtronic PLC (MiniMed)
10. Nemaura Medical
11. Novo Nordisk
12. Roche
13. Senseonics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support